Description
Matrix GLa protein inhibits vascular calcification in a vitamin K-dependent manner. Serum levels of this peptide may be used as a biomarker for renal failure, diabetes, and cardiovascular events.
Product Unit Size | Cost | Quantity | Stock |
---|
Matrix GLa protein inhibits vascular calcification in a vitamin K-dependent manner. Serum levels of this peptide may be used as a biomarker for renal failure, diabetes, and cardiovascular events.
Purity | ≥95% |
---|---|
Formula | C18H25N5O5S |
Formula Wt. | 423.4 |
Synonym | MGP-pNa |
Solubility | Soluble in water. |
Appearance | White to off white powder |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
Info Sheet |
---|
McCarty MF, DiNicolantonio JJ. The molecular biology and pathophysiology of vascular calcification. Postgrad Med. 2014 Mar;126(2):54-64. PMID: 24685968.
Schurgers LJ, Uitto J, Reutelingsperger CP. Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization. Trends Mol Med. 2013 Apr;19(4):217-26. PMID: 23375872.
Galactose-derived hexosamine sugar, component o...
Statin; HMG-CoA reductase inhibitor.
Thymidylate synthase inhibitor, potential SHMT,...
Somewhat selective in inhibiting COX-2 over COX...
Steroid hormone involved in stress signaling; g...
Aminoglycoside; protein translation inhibitor, ...
Prodrug
Renin inhibitor.
Vitamin E component
Fungal pigment found in red yeast rice
Isothiocyanate found in cruciferous vegetables,...
Src and Abl inhibitor.
Peptide, derivative of AT I, cleavage product o...
Phytohormone
EGFR inhibitor.
Glycoprotein IIb/IIIa inhibitor.
Diterpene found in Taxus; potential microtubule...
Somatostatin analog, peptide; somatostatin agon...
Triadimefon metabolite; mutagen.
S-enantiomer of citalopram; SERT inhibitor.